Hyperfine Secures CDSCO Approval to Launch AI-Powered Portable MRI System in India

Hyperfine, Inc., the US-based health technology company behind the world’s first FDA-cleared AI-powered portable MRI system for the brain, has received regulatory approval in India. The Central Drugs Standard Control Organisation (CDSCO) has cleared Hyperfine’s Swoop® portable MRI system, paving the way for its commercial rollout across the country.

This approval opens access to advanced brain imaging in one of the world’s largest healthcare markets, where the need for scalable and affordable neuroimaging solutions remains significant.

What the CDSCO Approval Means?

With CDSCO clearance in place, Hyperfine can now commercialise the Swoop® system throughout India. The company will distribute the technology through a strategic partnership with Radiosurgery Global (RSG), a medical device distributor with deep expertise in advanced imaging and a strong national footprint.

This partnership combines:

• Hyperfine’s portable, AI-powered brain MRI technology
• RSG’s regulatory expertise, hospital access, and on-ground execution capabilities

Together, the companies aim to accelerate adoption across India’s healthcare ecosystem.

Addressing India’s Neuroimaging Gap

India faces a stark imbalance between population size and access to MRI infrastructure. Despite serving more than 1.4 billion people, the country has far fewer MRI scanners per capita compared to developed markets.

Key challenges include:

• High capital costs of conventional MRI systems
• Complex infrastructure and space requirements
• Limited access outside major urban hospitals

The Swoop® system is designed to overcome these barriers by offering portable, lower-cost brain imaging that can be deployed in a wider range of care settings.

Why the Swoop® Portable MRI Matters?

Hyperfine’s Swoop® system is the first AI-powered portable MRI cleared by the US FDA for brain imaging. Its portability allows imaging to be performed closer to the patient, reducing delays and expanding access in resource-constrained environments.

In the Indian context, this could support:

• Faster neurological diagnosis
• Expanded imaging access beyond tertiary care centres
• Improved care delivery in emergency, ICU, and remote settings

Industry Perspective

Commenting on the collaboration, Kapil Kalra, Managing Director at Radiosurgery Global, said the partnership brings together complementary strengths to address a critical unmet need.

The alliance aims to translate advanced imaging innovation into real-world clinical impact across India’s diverse healthcare landscape.

Looking Ahead

With regulatory approval secured and a local distribution partner in place, Hyperfine is positioned to tap into a high-growth market with a strong demand for accessible neuroimaging solutions. The Indian launch marks a key milestone in the company’s global expansion strategy—and a potential step forward in improving brain care access at scale.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!